Q9981 HCPCS Level II code: Rolapitant, oral, 1 mg
CMS terminated Q9981: its last date of service was Dec 31, 2016. It stays here for looking up older claims; newer services need a current code.
Official description
Q9981Rolapitant, oral, 1 mg
Short description: Rolapitant, oral, 1mg
HCPCS · United States
Notes for Q9981
As CMS prints them, with any note Q9981 takes from the headings above it.
Note
- CMS processing note 0187: PUB. 100-4, CHAPTER 17.
Medicare details
The indicators CMS publishes with Q9981 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Drugs
- Type of service
- Medical care
- BETOS category
- Other drugs
- Cross-reference
- See J8670
- Added
- Jul 1, 2016
- Terminated after
- Dec 31, 2016
Where Q9981 sits
- 1Q codesTemporary codes
- 2Terminated Q9981Rolapitant, oral, 1 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
Is HCPCS code Q9981 still valid?
No. CMS terminated Q9981; its last date of service was Dec 31, 2016. It is listed for looking up services from before then. Use a current code for newer services.
Does Medicare cover Q9981?
CMS lists Q9981’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside Q9981
All Q codesQ9975Injection, factor viii fc fusion protein (recombinant), per iuQ9976Injection, ferric pyrophosphate citrate solution, 0.1 mg of ironQ9977Compounded drug, not otherwise classifiedQ9978Netupitant 300 mg and palonosetron 0.5 mgQ9979Injection, alemtuzumab, 1 mgQ9980Hyaluronan or derivative, genvisc 850, for intra-articular injection, 1 mgQ9982Flutemetamol f18, diagnostic, per study dose, up to 5 millicuriesQ9983Florbetaben f18, diagnostic, per study dose, up to 8.1 millicuriesQ9984Levonorgestrel-releasing intrauterine contraceptive system (kyleena), 19.5 mgQ9985Injection, hydroxyprogesterone caproate, not otherwise specified, 10 mgQ9986Injection, hydroxyprogesterone caproate, (makena), 10 mgQ9987Pathogen(s) test for platelets